Quarterly report · Q2
6523.TEDINET S100PICM
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥170.6bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥89.1bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥166.1bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥85.1bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥10.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥8.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥13.5bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥7.9bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥9.7bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.0bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥15.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.6bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥8.5bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥15.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥4.6bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥596.3bn | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥591.3bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥569.2bn | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥446.9bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥455.3bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥149.3bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥124.1bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥107.6bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥148.3bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥123.5bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥73.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥59.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥5.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥20.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥8.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥20.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥14.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥9.61 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥66.6 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥129.06 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.67 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥9.52 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥65.98 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥125.01 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥38.42 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 24.9% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 21.7% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥9.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥55.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥55.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥49.3bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥49.3bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥64.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥64.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥169.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥169.5bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥20.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥8.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥53.7bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥53.7bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥10.5bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥66.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥66.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥8.8bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥164.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥164.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥22.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 976
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from sale of businesses inv cf IFRS | CurrentYTDDuration | － | JPY |
| Purchase of investments accounted for using equity method inv cf IFRS | Prior1YTDDuration | -985000000 | JPY |
| Purchase of investments accounted for using equity method inv cf IFRS | CurrentYTDDuration | － | JPY |
| Purchase of investments inv cf IFRS | Prior1YTDDuration | -755000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYTDDuration | -290000000 | JPY |
| Proceeds from sale of investments inv cf IFRS | Prior1YTDDuration | 2008000000 | JPY |
| Proceeds from sale of investments inv cf IFRS | CurrentYTDDuration | － | JPY |
| Other inv cf IFRS | Prior1YTDDuration | -226000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | -723000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -6821000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -8425000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YTDDuration | -444000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | -234000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YTDDuration | 311348000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -322683000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -12924000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -2614000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -2912000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from issuance of shares fin cf IFRS | CurrentYTDDuration | 182000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -359000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | － | JPY |
| Proceeds from sale of treasury shares fin cf IFRS | Prior1YTDDuration | 36000000 | JPY |
| Proceeds from sale of treasury shares fin cf IFRS | CurrentYTDDuration | － | JPY |
| Dividends paid to owners of parent fin cf IFRS | Prior1YTDDuration | － | JPY |
| Dividends paid to owners of parent fin cf IFRS | CurrentYTDDuration | -4704000000 | JPY |
| Other fin cf IFRS | Prior1YTDDuration | -41000000 | JPY |
| Other fin cf IFRS | CurrentYTDDuration | 4000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -14759000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -20589000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 165000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 2041000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -1160000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -21519000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 60762000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 95232000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 59601000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 73713000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember | 53734000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember | 66869000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 44037000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 164641000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | 1409000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 166051000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |